Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Progress in the development of piperaquine combinations for the treatment of malaria

DSpace/Manakin Repository

Show simple item record D'Alessandro, U. 2009-12-18T15:24:47Z 2009-12-18T15:24:47Z 2009
dc.identifier.issn 0951-7575
dc.identifier.issn ABSTRACT
dc.identifier.other ITG-PUA
dc.identifier.other PARAS
dc.identifier.other U-MALAR
dc.identifier.other JIF
dc.identifier.other DOI
dc.identifier.other UPD17
dc.description.abstract PURPOSE OF REVIEW: Dihydroartemisinin-piperaquine is a new and extremely promising artemisinin-containing fixed-combination antimalarial, about to be registered with international regulatory authorities such as the European Medicines Agency. A formulation produced according to good manufacturing practices should be available soon. RECENT FINDINGS: Piperaquine is characterized by a slow absorption, long mean terminal elimination half-life and large mean volume distribution. However, children, compared to the population mean profile, tend to have a smaller central volume of distribution, a shorter distribution half-life and a more rapid fall in early piperaquine plasma concentrations, suggesting that an increase of the weight-adjusted dosage in children may be required. In addition, the oral bioavailability of piperaquine improves when given with a high-fat meal, though this does not necessarily translate into a higher efficacy. Several clinical trials have repeatedly shown that dihydroartemisinin-piperaquine is well tolerated and efficacious, with the only exception of one trial recently carried out in Papua New Guinea. Patients treated with dihydroartemisinin-piperaquine may have a higher rate of person-gametocyte-weeks, though it is unclear whether this translates into a higher infectiousness to biting anophelines. SUMMARY: The dosage recommended for children may need to be reviewed and the usefulness of the coadministration with food should be determined. Establishing safety and efficacy of this treatment in pregnancy remains a priority. en
dc.language English en
dc.subject Protozoal diseases en
dc.subject Malaria en
dc.subject Drug development en
dc.subject Antimalarials en
dc.subject Combination therapy en
dc.subject Dihydroartemisinin-piperaquine en
dc.subject Drug administration en
dc.subject Safety en
dc.title Progress in the development of piperaquine combinations for the treatment of malaria en
dc.type Article en
dc.citation.issue 6 en
dc.citation.jtitle Current Opinion in Infectious Diseases en
dc.citation.volume 22 en
dc.citation.pages 588-592 en
dc.citation.jabbreviation Curr Opin Infect Dis en

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record